Eisai's breast cancer treatment eribulin gained priority-review designation from the FDA. The drugmaker said the agency will decide on the product's approval by Sept. 30.
Published in Brief:
|Compliance and Ethics Director||
Sysmex America, Inc.
|Director, Site Quality Management||
|Palm Springs, CA|
|Compliance Officer-Medical Products||
W. L. Gore